Mylan is the world's third largest generic drug company, and makes a number of generic medications. Allegedly, Mylan was involved in falsifying information and altering products, possibly for as long as two years or more. It's not clear if the quality of their products -- which include various generic thyroid medications, among other generic drugs -- was affected.
The U.S. Food and Drug Administration has said that it is now investigating Mylan. Mylan issued a statement suggesting that the FDA investigation was routine, but the FDA took the unusual step of issuing a statement to refute and rebut Mylan's efforts to downplay the severity of the investigation.
The Pittsburgh Post-Gazette is ground zero for investigation and coverage of the Mylan scandal, as you'll see from these links to the coverage.
- Mylan workers overrode drug quality controls, Internal report detailed 'pervasive' practice of ignoring safety procedures -- Pittsburgh Post Gazette, Sunday, July 26, 2009
- Mylan's 'red screen' timeline -- Pittsburgh Post Gazette, Sunday, July 26, 2009
- FDA probing Mylan's actions, Quality control violations were cited in internal report -- Pittsburgh Post Gazette, Tuesday, July 28, 2009
- "FDA refutes Mylan statement" -- Pittsburgh Post Gazette, Tuesday, July 28, 2009
What Should Thyroid Patients Do?
We've always known that many doctors do NOT recommend that thyroid patients take generic levothyroxine from any maker, including Mylan.
No one knows whether there are quality or consistency issues with Mylan's generic T3 at this point. But there is not a great cost differential between brand name Cytomel and the generic liothyronine from Mylan. So, at this point, patients may consider waiting a while to see how this Mylan scandal shakes out before being willing to change over to their generic T3 medication.